Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.

× No keyword cloud information.

33 in total

Review 1. Antisense technology: an overview and prospectus.

Authors: Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal: Nat Rev Drug Discov Date: 2021-03-24 Impact factor: 84.694

2. 21st Century Cures Bill May Lead To Faster Drug/Device Approvals: But Moving Away from Clinical Trials Worries Some.

Authors: Stephen Barlas
Journal: P T Date: 2017-02

3. Giving Patients a Meaningful Voice in United States Regulatory Decision Making: The Role for Health Preference Research.

Authors: F Reed Johnson; Kathleen Beusterien; Semra Özdemir; Leslie Wilson
Journal: Patient Date: 2017-08 Impact factor: 3.883

4. Symposium Title: Preference Evidence for Regulatory Decisions.

Authors: Juan Marcos Gonzalez; F Reed Johnson; Bennett Levitan; Rebecca Noel; Holly Peay
Journal: Patient Date: 2018-10 Impact factor: 3.883

5. Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's Ataxia.

Authors: Lili Guo; Qingqing Wang; Liwei Weng; Lauren A Hauser; Cassandra J Strawser; Agostinho G Rocha; Andrew Dancis; Clementina Mesaros; David R Lynch; Ian A Blair
Journal: Anal Chem Date: 2018-01-11 Impact factor: 6.986

6. Magnetic resonance imaging in facioscapulohumeral muscular dystrophy.

Authors: Doris G Leung
Journal: Muscle Nerve Date: 2018-01-23 Impact factor: 3.217

7. An Evidence-Based, Community-Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials.

Authors: Rebecca R Moultrie; Megan A Lewis; Ryan S Paquin; Ann Lucas; Jill Jarecki; Holly L Peay
Journal: J Genet Couns Date: 2017-12-20 Impact factor: 2.537

8. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Authors: Yusuke Echigoya; Kenji Rowel Q Lim; Nhu Trieu; Bo Bao; Bailey Miskew Nichols; Maria Candida Vila; James S Novak; Yuko Hara; Joshua Lee; Aleksander Touznik; Kamel Mamchaoui; Yoshitsugu Aoki; Shin'ichi Takeda; Kanneboyina Nagaraju; Vincent Mouly; Rika Maruyama; William Duddy; Toshifumi Yokota
Journal: Mol Ther Date: 2017-07-28 Impact factor: 11.454

Review 9. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy.

Authors: Kasia Dzierlega; Toshifumi Yokota
Journal: Gene Ther Date: 2020-06-01 Impact factor: 5.250

Review 10. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors: Carlo Rinaldi; Matthew J A Wood
Journal: Nat Rev Neurol Date: 2017-12-01 Impact factor: 42.937